PHARMA INDUSTRY
Budget 2024: Pharma sector seeks tax sops, effective intellectual property rights regime
Union Budget: Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.
Pankaj Pandey on 3 stocks to bet on from pharma sector
We have been very selective in terms of chasing stocks because our sense is that you need to see stocks for a considerable period of time before we recommend. IREDA is what we have sort of recommended because our sense is that this one PSU AAA rated can deliver 30% kind of AUM growth while valuations are on a higher side, but we like the opportunity size.
Dr Reddy's, Sun Pharma recall drugs in US market: USFDA
Dr Reddy's Laboratories and Sun Pharma are recalling products in the US due to manufacturing issues, as per the latest USFDA Enforcement Report. Dr Reddy's is recalling insomnia and gout drugs, with 13,752 bottles of Eszopiclone tablets affected by failed impurities at their Bachupally plant. Sun Pharma is recalling 2,088 vials of Decitabine for Injection due to CGMP deviations at their Gujarat plant, prompting Class II recalls by both companies.
What should investors do with HDFC Bank stocks? Rahul Shah answers
So, a good IPO and the way they have priced it also, as you rightly said, that very reasonably priced and some money to be made on the table for the investors and in a pharma pack when we are seeing that most of the pharma packs are doing quite well and the way the segment which has been into Emcure is into, so all the front they have been firing at this point of time.
India best emerging market story; haven't ever seen valuations and fundamentals so attractive: Mihir Vora
The US economy has been much better than expected. It has been stronger for longer and of course, then it also translates to higher interest rates for longer, probably, but the fact is that the US economy is doing quite well.
3M India, M&M among 25 stocks that will trade ex-dividend this week. Do you own any?
Dividends are distributed to shareholders whose names are listed in the company's records on the record date. With the adoption of the T+1 settlement system, the record date and ex-dividend date are usually identical, except when market holidays occur immediately following the ex-date. Investors who buy the stock at least one day before the ex-date qualify for dividends, as settlement happens on the ex-date.
- Go To Page 1
Indian regulator says 36% of inspected drug-making units had to be shut
India's drug regulator has ordered the closure of over 36% of its 400 drug manufacturing units since last year due to concerns over sub-standard cough syrups. The country, known as the world's pharmacy due to its large drug production, is working to restore confidence after the deaths of over 300 children worldwide linked to these syrups.
Indian Pharma exports: 'USD 10 billion opportunity up for grabs in off patent drug market by 2029'
A senior official of the Pharmexcil said drugs such as Merck's Pembrolizumab (Keytruda) whose revenue were at USD 25 billion and Bristol-Myers Squibb's Eliquis (Apixaban)-USD 12 billion, among others would be off-patented in the next few years.
India pharma units fare better in US checks in 2023
The drug regulator United States Food and Drug Administration (USFDA) has classified 13%, or 19 out of 145 inspections it carried out against Indian facilities, as Official Action Indication (OAI) in 2023, which is lower than the global average of 15% OAIs, according to a report by Indian Pharmaceutical Alliance and McKinsey & Company said.
3 top stock recommendations from CA Rudramurthy BV
Let us see how even budget comes out and then take aggressive position. So, for sure, this is not the time to take aggressive position, not to be in high beta and one has to have reduced leverage and risk management will hold the key if you are a very short-term trader.
Sun Pharma completes merger of Taro
As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates. As a result of the merger, Taro will be delisted from the NYSE and it becomes a privately held company 100% owned by Sun Pharma.
Auto & FMCG stocks offer support as Sensex settles 131 points higher; Nifty tops 23,500
Investors traded cautiously amid sectoral swings. Sensex closed around 77,341, Nifty sealed the day at 23,538. Sectorally, the gains were led by auto stocks, whose index was up nearly 0.9% and the FMCG pack, which rose around 0.72%. The Nifty IT, metal, PSU bank and pharma indices spoiled the market mood.
High costs of orphan drugs: Patients pay the price for policy hurdles in India
India manufactures APIs for over 400 FDA-approved orphan drugs, but patients face high costs due to Indian pharmaceutical companies' reluctance to develop these drugs domestically.
Taller, stronger, sharper: Desi pharma is on a roll
The Avendus Capital report attributed the eye-catching growth of large Indian pharma brands to lifestyle diseases, prevalent quality issues that made doctors and customers rely more on big, well-known brands, along with aggressive sales and marketing push by pharma companies.
Sun Pharma inks pact with Takeda to introduce gastrointestinal drug in India
Sun Pharmaceutical Industries announced a licensing deal with Takeda Pharmaceutical to market Vonoprazan, a novel gastrointestinal drug, in India. The agreement allows Sun Pharma to commercialize 10 mg and 20 mg tablets of Vonoprazan, an innovative treatment for acid peptic disorders, under a non-exclusive patent license.
Nifty target price increased to 25,638; HDFC Bank among 19 conviction picks: InCred Equities
As the VIX returns to a near-13 level, a domestic brokerage firm reaffirms its optimistic outlook for the Indian market. The firm highlights robust macroeconomic factors and projects 12% EPS growth for FY25-26, favoring investments in the utility, consumer, and capital goods sectors.
Ozempic frenzy lures rich Indians to brave the gray market
People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage, fueling a high demand. According to Goldman Sachs Research, the anti-obesity medication market could hit $100 billion by 2030. In contrast, Indians have largely been observers in this global frenzy over the new weight-loss solutions.
Expert panel to soon weigh plan to use generics for prescription drugs
An expert committee is set to discuss the feasibility of allowing generic substitutions for prescription drugs in India. The proposal has sparked a disagreement between the Indian Pharmaceutical Alliance (IPA) and the All India Drug Action Network (AIDAN). The IPA opposes the idea, arguing that it would lead to a surge of demand from trade channels, such as general pharmacy stores, which would not benefit patients.
Pharma industry raises concerns over new Schedule M's impact on cosmetic manufacturing
The pharmaceutical industry, represented by the Federation of Pharma Enterprises (FoPE), has expressed concerns over the government's new Schedule M, which prohibits the manufacture of any product other than drugs in units licensed for drug production. FoPE argues that setting up a separate plant for cosmetic manufacturing is financially unviable for medium and small-scale enterprises. They are requesting permission to manufacture cosmetics in the area designated for topical products like creams and lotions.
Sun Pharma expects high single-digit top line growth in current fiscal
Sun Pharmaceutical Industries expects high single-digit top line growth in FY24 with total revenue at Rs 48,497 crore, led by Managing Director Dilip Shanghvi. The firm anticipates similar growth in FY25 with investments in product launches and R&D activities.
India's pharma export sales to grow faster this year
India's pharmaceutical exports are projected to grow nearly 11% this fiscal year, up from about 10% last year, driven by the U.S. and UK markets, according to Pharmexcil. Exports are expected to surpass $31 billion, rising from nearly $28 billion in fiscal 2024, despite quality concerns following cough syrup-linked deaths.
Pharma bosses told to submit affidavits on ethical practices
Pharmaceutical companies asked to submit undertaking to government for compliance with UCPMP 2024 by June 30, as per DoP circular dated May 28.
Panel to examine if nutraceuticals can be produced within drug unit
In a significant development, a five-member expert committee has been appointed to assess the feasibility of allowing the manufacturing of nutraceuticals within drug manufacturing facilities in India. This decision comes after the country's drug regulator had previously warned of taking action against those violating regulations by producing supplements and drugs in the same facility.
ChrysCapital sets sights on pharma buyout deals
ChrysCapital, led by MD Kshitij Sheth, aims to acquire Indian companies in the formulation business with potential valuations of $200 million-$500 million, focusing on growth and eventual public listings.
New plant of Sun Pharma inaugurated in Bangladesh
Indian pharmaceutical company, Sun Pharma, inaugurated a new plant in Bangladesh, strengthening economic ties and promoting collaboration in the pharmaceutical sector, including joint R&D efforts.
Sun Pharma to pursue M&A, licensing to expand speciality business
Sun Pharma, India's leading pharmaceutical company, plans to pursue licensing and acquisitions as part of its strategy to grow its specialty business, according to a senior executive of the company. The executive noted that in recent years, Sun Pharma has been actively working on building a portfolio of products internally. Moving forward, the company intends to adopt a dual approach, combining both mergers and acquisitions with in-house product development.
Local pharma companies queue up for JB Chemicals & Pharmaceuticals
Mankind Pharma, Dr Reddy's Laboratories, and Torrent Pharma are interested in acquiring JB Chemicals & Pharmaceuticals from KKR. KKR's investment arm, TAU Investment, owns 53.78% in JB Chemicals, worth Rs 14,020 crore. The company's revenue doubled to Rs 3,484 crore in FY24 under KKR's ownership. JB Chemicals has made four acquisitions in the last four years, investing $200 million. However, global private equity funds are not pushing for JB Chemicals due to high valuations.
Indian pharmaceutical industry set for major transformation: Dilip Shanghvi
At an annual meeting of the USA-India Chamber of Commerce in Boston, Shanghvi told a gathering of leading multinational drug makers about the "clear positive improvements" that are taking place in India. Sun Pharma itself has built a pipeline of over 10 specialty and innovative drugs in the US. It's done this through acquisitions of late-stage drugs in clinical trials and building commercial teams around them. For Indian companies that have grown by making copies of innovative drugs, gaining presence in innovative drugs is considered tough as this segment is dominated by giant corporations such as Pfizer, Novartis, Roche, Eli Lilly and Bristol Myers Squibb.
India becoming attractive for clinical trials, says pharma industry leaders
Over the past decade, India has seen significant improvements in its clinical trial landscape, with a 15-18% growth in phase two and three trials. This growth is attributed to 10 modifications to the Drugs and Cosmetics Act since 2013, aimed at simplifying the process. Despite these advancements, conducting trials in India can still be challenging. Experts note that India's modernizing private hospital networks and improved infrastructure make it an attractive location for trials, with potential for further growth and collaboration in the future.
Load More
